[1]PORTER R N,SMITH W,CRAFT I L,et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins[J]. Lancet,1984,2(8414):1284-1285.
[2]FRYDMAN R,CORNEL C,DE ZIEGLER D,et al. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist,Nal-Glu,in controlled ovarian hyperstimulation[J]. Fertility and sterility,1991,56(5):923-927.
[3]SCHALLY A V,ARIMURA A,BABA Y,et al. Isolation and properties of the FSH and LH-releasing hormone[J]. Biochemical and biophysical research communications,1971,43(2):393-399.
[4]CHEN A,YAHALOM D,BEN-AROYA N,et al. A second isoform of gonadotropin-releasing hormone is present in the brain of human and rodents[J]. FEBS letter,1998,435(2-3):199-203.
[5]HISLOP J N,MADZIVA M T,EVEREST H M,et al. Desensitization and internalization of human and xenopus gonadotropin-releasing hormone receptors expressed in alphaT4 pituitary cells using recombinant adenovirus[J]. Endocrinology,2000,141(12):4564-4575.
[6]MAGGI R,CARIBONI A M,MARELLI M M,et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system[J]. Human reproduction update,2016,22(3):358-381.
[7]TARLATZIS B C,BILI H N. Gonadotropin-releasing hormone antagonists:impact of IVF practice and potential non-assisted reproductive technology applications[J]. Current opinion in obstetrics & gynecology,2003,15(3):259-264.
[8]NIEDERBERGER C,PELLICER A,COHEN J,et al. Forty years of IVF[J]. Fertility and sterility,2018,110(2):185-324.
[9]MACKLON N S,STOUFFER R L,GIUDICE L C,et al. The science behind 25 years of ovarian stimulation for in vitro fertilization[J]. Endocrine reviews,2006,27(2):170-207.
[10]BROKEMANS F J,BEMARDUS R E,BERKHOUT G. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation:Decapeptyl CR[J]. Gynecol endom'nol,1992,6(3):153-161.
[11]MELDRUM D R,WISOT A,HAMILTON F,et al. Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression[J]. Fertility and sterility,1988,50(3):400-402.
[12]RON-EL R,HERMAN A,GOLAN A,et al. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist[J]. Fertility and sterility,1990,54(2):233-237.
[13]URBANCSEK J,WITTHAUS E. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization[J]. Fertility and sterility,1996,65(5):966-971.
[14]EDWARDS R G,MORCOS S,MACNAMEE M,et al. High fecundity of amenorrhoeic women in embryo-transfer programmes[J]. Lancet,1991,338(8762):292-294.
[15]REN J,SHA A,HAN D,et al. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?[J]. Fertility and sterility,2014,102(1):75-81.
[16]ZHANG Y,ZHAO W,HAN Y,et al. The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol:a single-centre,retrospective,propensity score matched cohort study[J]. Reproductive biology and endocrinology,2022,20(1):140.
[17]XU B,GEERTS D,HU S,et al. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle,but not the cumulative live birth rate in normal responders:a randomized controlled trial and molecular mechanism study[J]. Human reproduction,2020,35(6):1306-1318.
[18]AL-INANY H G,YOUSSEF M A,AYELEKE R O,et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology[J]. Cochrane database of systematic reviews,2016,4(4):CD001750.
[19]YANG J,ZHANG X,DING X,et al. Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred:real-word data of 18,853 women from China[J]. Reproductive biology and endocrinology,2021,19(1):124.
[20]HUANG Y,SHUAI M,YUE L,et al. Application of antagonist regimen in patients with failed pregnancy assisted by previous long-term regimen during early follicular phase[J]. American journal of translational research,2021,15; 13(7):8365-8371.
[21]KHALAF M,MITTRE H,LEVALLET J,et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation:differential regulation pathway of aromatase expression in human granulosa cells[J]. Reproductive biomedicine online,2010,21(1):56-65.
[22]WINKLER N,BUKULMEZ O,HARDY D B,et al. Gonadotropin releasing hormone antagonists suppress aromatase and anti-Müllerian hormone expression in human granulosa cells[J]. Fertility and sterility,2010,94(5):1832-1839.
[23]XU D F,LIU P P,FAN L,et al. GnRH antagonist weakens endometrial stromal cells growth ability by decreasing c-kit receptor expression[J]. Reproductive biology and endocrinology,2022,20(1):29.
[24]ZHANG D,HAN M,ZHOU M,et al. Down-regulation of S100P induces apoptosis in endometrial epithelial cell during GnRH antagonist protocol[J]. Reproductive biology and endocrinology,2021,19(1):99.
[25]CARDOZO E R,THOMSON A P,KARMON A E,et al. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls:a 17-year experience[J]. Journal of assisted reproduction and genetics,2015,32(4):587-596.
[26]NAJDECKI R,MICHOS G,PEITSIDIS N,et al. Agonist triggering in oocyte donation programs-Mini review[J]. Front endocrinol,2022,13:838236.
[27]CIMADOMO D,VAIARELLI A,PETRIGLIA C,et al. Oocyte competence is independent of the ovulation trigger adopted:a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer[J]. Journal of assisted reproduction and genetics,2021,38(6):1419-1427.
[28]王雪金,张宏展,胡晓东 等. 促性腺激素释放激素激动剂单扳机后不同反应对IVF-ET胚胎结局的影响[J]. 生殖医学杂志,2022,31(11):1506-1512.
[29]THORNE J,LOZA A,KAYE L,et al. Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin[J]. Fertility and sterility,2019,112(2):258-265.
[30]MIZRACHI Y,HOROWITZ E,FARHI J,et al. Ovarian stimulation for freeze-all IVF cycles:a systematic review[J]. Human reproduction update,2020,26(1):118-135.
[31]SHAPIRO B S,DANESHMAND S T,GARNER F C,et al. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization[J]. Fertility and sterility,2008,90(1):231-233.
[32]HU K L,WANG S,YE X,et al. GnRH agonist and hCG(dual trigger)versus hCG trigger for follicular maturation:a systematic review and meta-analysis of randomized trials[J]. Reproductive biology and endocrinology,2021,19(1):78.
[33]YAN M H,CAO J X,HOU J W,et al. GnRH agonist and hCG(Dual Trigger)versus hCG trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate:study protocol for a randomized,superiority,parallel group,controlled trial[J]. Front endocrinol,2022,13:831859.
[34]HAAS J,BASSIL R,SAMARA N,et al. GnRH agonist and hCG(dual trigger)versus hCG trigger for final follicular maturation:a double-blinded,randomized controlled study[J]. Human reproduction,2020,35(7):1648-1654.
[35]ZHOU C,YANG X,WANG Y,et al. Ovulation triggering with hCG alone,GnRH agonist alone or in combination?A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles[J]. Human reproduction,2022,37(8):1795-1805.
[36]SONG M,LIU C,HU R,et al. Administration effects of single-dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles:a meta-analysis of randomized controlled trials[J]. Experimental and therapeutic medicine,2020,19(1):786-796.
[37]TESARIK J,HAZOUT A,MENDOZA C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation[J]. Human reproduction,2004,19(5):1176-1180.
[38]FUSI F M,BRIGANTE C M,ZANGA L,et al. GnRH agonists to sustain the luteal phase in antagonist IVF cycles:a randomized prospective trial[J]. Reproductive biology and endocrinology,2019,17(1):103.
[39]KUNG H F,CHEN M J,GUUA H F,et al. Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal follicle-stimulating hormone or lower mature oocytes[J]. Journal of the Chinese medical association:JCMA,2014,77(10):524-530.
[40]SALANG L,TEIXEIRA D M,SOLA I,et al. Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse[J]. Cochrane database of systematic reviews,2022,(8):112.